Safety and clinical activity of avelumab (MSB0010718C), an anti-programed death-ligand 1 (PD-L1) antibody, in recurrent thymic epithelial tumors (TETs)Arun Rajan,Haobin Chen,Chen Zhao, Shannon Swift,Andrew Mammen,Alessandra Brofferio,Emerson Padiernos,Eva Szabo,Udayan Guha,Raffit Hassan,Seth Steinberg,Yo-Ting Tsai,Renee Donahue,Jeffrey Schlom,James GulleyJOURNAL FOR IMMUNOTHERAPY OF CANCER（2019）引用 1|浏览17暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
